Tabrecta is a medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC), when the cancer is advanced and its cells have particular genetic mutations (changes) leading to ‘mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping’. This means that the cancer cells make an abnormal form of a protein called MET, because a part of the MET gene known as exon 14 is not used. Tabrecta is used when the patient needs further treatment after receiving immunotherapy or platinum-based chemotherapy, or both. Tabrecta contains the active substance capmatinib.
Therapeutic Indication
### Therapeutic indication Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
Therapeutic Area (MeSH)
ATC Code
L01EX17
ATC Item
capmatinib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| capmatinib dihydrochloride monohydrate | N/A | capmatinib dihydrochloride monohydrate |
EMA Name
Tabrecta
Medicine Name
Tabrecta
Aliases
N/ANo risk management plan link.
